Humanized anti-IL-1R3 antibodies

Patent metadata

Field	Value
Publication number	US-12024564-B2
Application number	US-202117410153-A
Country	US
Kind code	B2
Filing date	Aug 24, 2021
Priority date	May 6, 2016
Publication date	Jul 2, 2024
Grant date	Jul 2, 2024

Abstract

The present invention relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity.
The invention further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer.
The present invention also encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.

First claim

The invention claimed is:

1. A method of treating cancer in a patient suffering therefrom, comprising administering to a patient an antibody that specifically binds to IL-1R3 or a fragment or derivative thereof, the antibody or fragment or derivative thereof comprising:
a) a heavy chain variable region (VH) comprising the complementarity determining regions comprising CDR-H1, CDR-H2, and CDR-H3
wherein the CDR-H1 region comprises an amino acid sequence set forth in SEQ ID NO: 77,
wherein the CDR-H2 region comprises an amino acid sequence set forth in SEQ ID NO: 94,
and wherein the CDR-H3 region comprises an amino acid sequence set forth in SEQ ID NO: 111; and

b) a light chain variable region (VL) comprising the complementarity determining regions comprising CDR-L1, CDR-L2, and CDR-L3
wherein the CDR-L1 region comprises an amino acid sequence set forth in SEQ ID NO: 128,
wherein the CDR-L2 region comprises an amino acid sequence set forth in SEQ ID NO: 145, and

wherein the CDR-L3 region comprises an amino acid sequence set forth in SEQ ID NO: 162.

2. The method of claim 1 , wherein the heavy chain variable (VH) region comprises an amino acid sequence set forth in SEQ ID NO: 26, and the light chain variable (VL) region comprises an amino acid sequence set forth in SEQ ID NO: 60.

3. The method of claim 1 , wherein the antibody or fragment or derivative thereof comprises a human IgG1 Fc region comprising at least amino acid substitutions at L234A and L235A of the human IgG1 Fc region, wherein the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system.

4. The method of claim 1 , wherein the cancer is selected from the group consisting of lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, or uterine cancer.

5. The method of claim 1 , wherein the antibody or fragment or derivative thereof comprises a human IgG4 Fc region comprising at least amino acid substitutions at S228P and L235E of the human IgG4 Fc region, wherein the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system.

6. The method of claim 1 , wherein the cancer is leukemia or lymphoma.

7. A method of treating cancer in a patient suffering therefrom, the method comprising administering to the patient a therapeutically effective amount of an antibody that specifically binds to IL-1R3 or a fragment or derivative thereof in combination with one or more cytotoxic, cytostatic or targeted anti-cancer compounds, wherein the antibody or fragment or derivative thereof comprises:
a) a heavy chain variable region (VH) comprising the complementarity determining regions comprising CDR-H1, CDR-H2, and CDR-H3
wherein the CDR-H1 region comprises an amino acid sequence set forth in SEQ ID NO: 77,
wherein the CDR-H2 region comprises an amino acid sequence set forth in SEQ ID NO: 94,
and wherein the CDR-H3 region comprises an amino acid sequence set forth in SEQ ID NO: 111; and

b) a light chain variable region (VL) comprising the complementarity determining regions comprising CDR-L1, CDR-L2, and CDR-L3
wherein the CDR-L1 region comprises an amino acid sequence set forth in SEQ ID NO: 128,
wherein the CDR-L2 region comprises an amino acid sequence set forth in SEQ ID NO: 145, and

wherein the CDR-L3 region comprises an amino acid sequence set forth in SEQ ID NO: 162.

8. A method of treating cancer in a patient, comprising administering to a patient an antibody that specifically binds to IL-1R3, wherein the antibody comprises:
a) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 26;
b) a VL region comprising an amino acid sequence set forth in SEQ ID NO: 60; and
c) a human IgG1 Fc region comprising at least amino acid substitutions at L234A and L235A of the human IgG1 Fc region, wherein the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system.

9. The method according to claim 8 , wherein the cancer is selected from the group consisting of lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, or uterine cancer.

10. The method of claim 8 , wherein the antibody is administered in combination with one or more cytotoxic, cytostatic or targeted anti-cancer compounds.

11. The method of claim 8 , wherein the cancer is leukemia or lymphoma.

12. A method of treating cancer in a patient, comprising administering to a patient an antibody that specifically binds to IL-1R3, the antibody comprising:
a) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 26;
b) a VL region comprising an amino acid sequence set forth in SEQ ID NO: 60; and
c) a human IgG4 Fc region comprising at least amino acid substitutions at S228P and L235E of the human IgG4 Fc region, wherein the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system.

13. The method according to claim 12 , wherein the cancer is selected from the group consisting of lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, or uterine cancer.

14. The method of claim 12 , wherein the antibody is administered in combination with one or more cytotoxic, cytostatic or targeted anti-cancer compounds.

15. The method of claim 12 , wherein the cancer is leukemia or lymphoma.

Assignees

• Sanofi Biotechnology

Inventors

• Fischer Stephan
• Brandt Michael
• Kazandjian Linda Veronique

Classifications

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61P35/00

  Antineoplastic agents · CPC title